High Vista Strategies LLC Affimed N.V. Transaction History

High Vista Strategies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $117,151 - $154,239	-21,816 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $46,430 - $62,941	8,381 Added 62.38%	21,816 $135,000
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $23,552 - $39,008	-4,600 Reduced 25.51%	13,435 $107,000
Q4 2020 Feb 16, 2021	SELL	$3.16 - $7.03 $19,481 - $43,339	-6,165 Reduced 25.48%	18,035 $105,000
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $10,432 - $15,136	3,200 Added 15.24%	24,200 $82,000
Q2 2020 Aug 14, 2020	SELL	$1.58 - $4.63 $20,066 - $58,801	-12,700 Reduced 37.69%	21,000 $97,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $27,000 - $36,840	12,000 Added 55.3%	33,700 $92,000
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $57,939 - $79,205	21,700 New	21,700 $64,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.